Q1FY25 Quarterly Result Announced for Aurobindo Pharma Ltd.
Pharmaceuticals company Aurobindo Pharma announced Q1FY25 results:
- Revenue from Operations increased by 10.5% YoY to Rs 7,567 crore with growth across the businesses
- US formulations (excluding Puerto Rico) revenue increased by 13.3% YoY to Rs 3,555 crore (USD 426 million)
- Europe formulations revenue increased by 7.9% YoY to Rs 1,982 crore (EUR 221 million)
- Growth Markets revenue increased by 49.2% YoY to Rs 709 crore (USD 85 million)
- ARV revenue increased by 13.9% YoY to Rs 229 crore (USD 27 million)
- API revenue grew by 5.6% YoY to Rs 1,092 crore (USD 131 million)
- EBITDA before Forex and Other Income stood at Rs 1,620 crore; EBITDA margin at 21.4%
- Research & Development (R&D) spend was Rs 339 crore, 4.5% of revenues
- Received final approval for 10 ANDAs including 1 Specialty & Injectable product from the USFDA
- Net Profit after Share of Profit/Loss of JV and Minority Interest at Rs 919 crore, vs. Rs 571 crore in Q1FY24
- Basic & Diluted EPS grew by 61.4% YoY to Rs 15.69 per share
Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments. Our profitability was sustained by improved gross margins and operational efficiencies, while ramping-up our recently commercialized plants. We are confident in our ability to achieve our growth targets for FY25.”